Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

ProQR Therapeutics

Main focus: RNA therapies for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases (gene editing): Genetic disorders in the liver and nervous system

Genome editing tool: ADAR RNA editing

Funding stage: Private

Location: Leiden, Netherlands and Cambridge, MA, USA

Website: https://www.proqr.com/

Pipeline:https://www.proqr.com/pipeline

Gene editing partnerships: Eli Lilly

ProQR Therapeutics develops transformative RNA therapies for the treatment of severe genetic rare diseases. Its has developed its own proprietary RNA editing technology tha involves the recruitment of the ADAR enzyme for RNA editing. The company is currently developing the technology at pre-clinical level, and has also established a collaboration with Eli Lilly, which has been granted access to use the technology.

Tags

HashtagProQR Therapeutics

Company: ProQR Therapeutics
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine